百合素在减轻肥胖引起的心脏重塑中的作用:对炎症和MMP-2通路的洞察
Carol Cristina Vagula de Almeida de Silva1,2, Artur Junio Togneri Ferron1, Fabiane Valentini Francisqueti-Ferron1
1Medical School, Sao Paulo State University (UNESP), Botucatu, Brazil.
Molecular nutrition & food research
|January 27, 2026
概括
烯补充剂通过减少炎症和保护心脏组织,改善了肥胖大鼠的心脏功能. 这种抗氧化剂可能有助于治疗与肥胖有关的心脏疾病.
科学领域:
- 心血管科学 心血管科学
- 营养科学 营养科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖导致慢性炎症和心脏重塑,导致心脏功能障碍.
- 矩阵金属蛋白酶-2 (MMP-2) 激活有助于肥胖患者的心肌原蛋白降解.
- 抗氧化和抗炎化合物正在研究肥胖症的心脏保护作用.
研究的目的:
- 评估烯在预防和治疗肥胖引起的心脏重塑方面的潜力.
- 评估柳科对炎症,MMP-2活性和心脏功能的影响.
- 为了确定利科是否能保持心肌原蛋白的完整性.
主要方法:
- 雄性Wistar大鼠被食高糖,高脂肪 (HSF) 饮食以诱导肥胖和心脏功能障碍.
- 在心脏功能障碍发作后,Lycopene (10 mg/kg/天) 已被使用了10周.
- 评估了代谢参数,心脏结构,心脏功能,炎症标志物和MMP-2活性.
主要成果:
- HSF饮食诱导高血压,肥胖,胰岛素抵抗,心脏重塑,炎症和升高的MMP-2.
- 百合素逆转了胰岛素抵抗,缓解了心脏重塑,并改善了心/心腹功能.
- 百合素降低了炎症标志物 (TNF-α,IL-6,NF-κB,TLR-4),降低了MMP-2激活,并增强了TIMP-2/原表达.
结论:
- 在肥胖引起的心脏重塑中,烯表现出显著的心脏保护和抗炎作用.
- 通过向炎症和细胞外基质降解,烯为与肥胖有关的心脏疾病提供了治疗策略.
- 百合素可以作为一种有效的辅助疗法,用于预防或治疗肥胖的心脏并发症.
相关概念视频
Inflammatory Response
12.5K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
12.5K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


